According to the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD), SGLT2 inhibitors should be discontinued during acute illness, including infections or any condition associated with decreased oral intake or volume depletion [13,14]. This evidence concerns the gene SLC5A2 and diabetes mellitus.